Occurrence and perdictive factors of radiation pneumonitis in patients with thoracic tumor

Abstract

Abstract:

Radiation pneumonitis is a common complication in the radiotherapy for thoracic malignant tumors. And the resulting respiratory failure is one of the most serious side effects. The occurrence and severity of radiation pneumonitis depend on many factors such as age, performance status scores, smoking status, lung condition, tumor sizes, tumor location, chemoradiotherapy related factors, inflammatory factors and single-nucleotide polymorphism,et al. Some imaging examinations, for example single-photon emission computed tomography and PET-CT, have been used to predict radiation pneumonitis, while its usefulness remains to be strengthened. Further researches are still needed to find the gold standard in the prediction of radiation pneumonitis.

Key words:Thoracic neoplasms,Radiotherapy,Radiation pneumonitis

Fu Lingli, Li Ping, Zhang Rui, Han Jianglong, Fu Zhenming. Occurrence and perdictive factors of radiation pneumonitis in patients with thoracic tumor[J]. Journal of International Oncology, 2020, 47(2): 107-111.

References36

[1]	郑荣寿, 孙可欣, 张思维 , 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005.
[2]	Palma DA, Senan S, Tsujino K , et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2013,85(2):444-450. DOI: 10.1016/j.ijrobp.2012.04.043. doi:10.1016/j.ijrobp.2012.04.043
[3]	Ding NH, Li JJ, Sun LQ . Molecular mechanisms and treatment of radiation-induced lung fibrosis[J]. Curr Drug Targets, 2013,14(11):1347-1356. DOI: 10.2174/13894501113149990198.
[4]	郑啓盛, 刘培勋 . 放射性肺纤维化的分子机制及其防治药物综述[J]. 辐射研究与辐射工艺学报, 2016,34(1):3-12. DOI: 10.11889/j.1000-3436.2016.rrj.34.010101.
[5]	Choi SH, Hong ZY, Nam JK , et al. A hypoxia-induced vascular endothelial-to-mesenchymal transition in development of radiation-induced pulmonary fibrosis[J]. Clin Cancer Res, 2015,21(16):3716-3726. DOI: 10.1158/1078-0432.Ccr-14-3193.
[6]	Richeldi L, Collard HR, Jones MG . Idiopathic pulmonary fibrosis[J]. Lancet, 2017,389(10082):1941-1952. DOI: 10.1016/s0140-6736(17)30866-8.
[7]	Giridhar P, Mallick S, Rath GK , et al. Radiation induced lung injury: prediction, assessment and management[J]. Asian Pac J Cancer Prev, 2015,16(7):2613-2617. DOI: 10.7314/apjcp.2015.16.7.2613.
[8]	Ozawa Y, Abe T, Omae M , et al. Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: retrospective analysis of patients with lung cancer[J]. PLoS One, 2015,10(10):e0140437. DOI: 10.1371/journal.pone.0140437.
[9]	Briere TM, Krafft S, Liao Z , et al. Lung size and the risk of radiation pneumonitis[J]. Int J Radiat Oncol Biol Phys, 2016,94(2):377-384. DOI: 10.1016/j.ijrobp.2015.10.002.
[10]	Torre-Bouscoulet L, Muñoz-Montaño WR, Martínez-Briseño D , et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung cancer[J]. Respir Res, 2018,19(1):72. DOI: 10.1186/s12931-018-0775-2.
[11]	Zhao J, Yorke ED, Li L , et al. Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies[J]. Int J Radiat Oncol Biol Phys, 2016,95(5):1357-1366. DOI: 10.1016/j.ijrobp.2016.03.024.
[12]	Liang J, Bi N, Wu S , et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage Ⅲ non-small cell lung cancer: a multicenter randomized phase Ⅲ trial[J]. Ann Oncol, 2017,28(4):777-783. DOI: 10.1093/annonc/mdx009.
[13]	Pan WY, Bian C, Zou GL , et al. Combing NLR, V₂₀and mean lung dose to predict radiation induced lung injury in patients with lung cancer treated with intensity modulated radiation therapy and chemotherapy[J]. Oncotarget, 2017,8(46):81387-81393. DOI: 10.18632/oncotarget.19032.
[14]	Giuliani ME, Lindsay PE, Kwan JY , et al. Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma[J]. Clin Lung Cancer, 2015,16(3):216-220. DOI: 10.1016/j.cllc.2014.11.008.
[15]	Hoover DA, Reid RH, Wong E , et al. SPECT-based functional lung imaging for the prediction of radiation pneumonitis: a clinical and dosimetric correlation[J]. J Med Imaging Radiat Oncol, 2014,58(2):214-222. DOI: 10.1111/1754-9485.12145.
[16]	Kim TH, Cho KH, Pyo HR , et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer[J]. Radiology, 2005,235(1):208-215. DOI: 10.1148/radiol.2351040248.
[17]	Kong FM, Hayman JA, Griffith KA , et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis[J]. Int J Radiat Oncol Biol Phys, 2006,65(4):1075-1086. DOI: 10.1016/j.ijrobp.2006.01.051.
[18]	Kharofa J, Cohen EP, Tomic R , et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2012,84(1):238-243. DOI: 10.1016/j.ijrobp.2011.11.013.
[19]	Zhao Y, Chen L, Zhang S , et al. Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer[J]. Thorac Cancer, 2015,6(1):49-57. DOI: 10.1111/1759-7714.12142.
[20]	Alharbi M, Janssen S, Golpon H , et al. Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage Ⅲ non-small cell cancer patients[J]. Radiat Oncol, 2017,12(1):165. DOI: 10.1186/s13014-017-0898-5.
[21]	Meng Y, Yang H, Wang W , et al. Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients[J]. Radiat Oncol, 2019,14(1):7. DOI: 10.1186/s13014-018-1204-x.
[22]	Zhuang H, Yuan Z, Chang JY , et al. Radiation pneumonitis in patients with non-small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy[J]. J Thorac Oncol, 2014,9(6):882-885. DOI: 10.1097/jto.0000000000000126.
[23]	Chiang CL, Chen YW, Wu MH , et al. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer[J]. J Chin Med Assoc, 2016,79(5):248-255. DOI: 10.1016/j.jcma.2016.01.008.
[24]	Shaverdian N, Lisberg AE, Bornazyan K , et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017,18(7):895-903. DOI: 10.1016/s1470-2045(17)30380-7.
[25]	Antonia SJ, Villegas A, Daniel D , et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017,377(20):1919-1929. DOI: 10.1056/NEJMoa1709937.
[26]	Wang S, Campbell J, Stenmark MH , et al. Plasma levels of IL-8 and TGF-beta1 predict radiation-induced lung toxicity in non-small cell lung cancer: a validation study[J]. Int J Radiat Oncol Biol Phys, 2017,98(3):615-621. DOI: 10.1016/j.ijrobp.2017.03.011.
[27]	Andreassen CN, Schack LM, Laursen LV , et al. Radiogenomics-current status, challenges and future directions[J]. Cancer Lett, 2016,382(1):127-136. DOI: 10.1016/j.canlet.2016.01.035.
[28]	Tucker SL, Li M, Xu T , et al. Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis[J]. Int J Radiat Oncol Biol Phys, 2013,85(1):251-257. DOI: 10.1016/j.ijrobp.2012.02.021.
[29]	Saito T, Nakayama H, Yamada T , et al. Is severe emphysema, as defined by quantitative CT measurement, a negative risk factor of radiation fibrosis?[J]. Br J Radiol, 2018,91(1087):20170921. DOI: 10.1259/bjr.20170921.
[30]	Abdulla S, Salavati A, Saboury B , et al. Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2014,41(2):350-356. DOI: 10.1007/s00259-013-2579-4. doi:10.1007/s00259-013-2579-4
[31]	Anthony GJ, Cunliffe A, Castillo R , et al. Incorporation of pre-therapy¹⁸F-FDG uptake data with CT texture features into a radiomics model for radiation pneumonitis diagnosis [J]. Med Phys, 2017,44(7):3686-3694. DOI: 10.1002/mp.12282.
[32]	Farr KP, Kramer S, Khalil AA , et al. Role of perfusion SPECT in prediction and measurement of pulmonary complications after radiotherapy for lung cancer[J]. Eur J Nucl Med Mol Imaging, 2015,42(8):1315-1324. DOI: 10.1007/s00259-015-3052-3.
[33]	Eslick EM, Stevens MJ, Bailey DL . SPECT V/Q in lung cancer radiotherapy planning[J]. Semin Nucl Med, 2019,49(1):31-36. DOI: 10.1053/j.semnuclmed.2018.10.009.
[34]	Vinogradskiy Y, Schubert L, Diot Q , et al. Regional lung function profiles of stage Ⅰ and Ⅲ lung cancer patients: an evaluation for functional avoidance radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2016,95(4):1273-1280. DOI: 10.1016/j.ijrobp.2016.02.058.
[35]	Faught AM, Miyasaka Y, Kadoya N , et al. Evaluating the toxicity reduction with computed tomographic ventilation functional avoidance radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2017,99(2):325-333. DOI: 10.1016/j.ijrobp.2017.04.024.
[36]	Krafft SP, Rao A, Stingo F , et al. The utility of quantitative CT radiomics features for improved prediction of radiation pneumonitis[J]. Med Phys, 2018,45(11):5317-5324. DOI: 10.1002/mp.13150.